CN103520498B - Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome - Google Patents

Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome Download PDF

Info

Publication number
CN103520498B
CN103520498B CN201310491607.XA CN201310491607A CN103520498B CN 103520498 B CN103520498 B CN 103520498B CN 201310491607 A CN201310491607 A CN 201310491607A CN 103520498 B CN103520498 B CN 103520498B
Authority
CN
China
Prior art keywords
medicinal composition
chinese medicinal
chinese medicine
cerebral arteriosclerosis
herba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310491607.XA
Other languages
Chinese (zh)
Other versions
CN103520498A (en
Inventor
李宪锋
艾洪艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201310491607.XA priority Critical patent/CN103520498B/en
Publication of CN103520498A publication Critical patent/CN103520498A/en
Application granted granted Critical
Publication of CN103520498B publication Critical patent/CN103520498B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome. The traditional Chinese medicine doctors think that the syndrome is caused by the deficiency of vitality, yin-fluid and blood, and moistening and nourishing in muscle and vessel or heart and kidney, emptiness of brain, dysfunction of the spleen in transport and the like. According to the Chinese medicinal composition, the Chinese medicines including conic gymnadenia tuber, swallowwort herb, hemipilia, medicinal indianmulberry roots, harbenaria herbs, curious kadsura fruits, rhizoma tupistrae chinensis, rust-brown crotalaria, sago leaf, African marigold, Indian scutellaria and rhodobryum, which have the functions of replenishing qi and invigorating the spleen, tonifying the liver and kidney, invigorating the circulation of the tires and dredging collaterals, are decocted with water to prepare decoction; the clinical test shows that the total effective rate is up to 95.0 percent, and the Chinese medicinal composition is obviously superior to that of a control group; moreover, the Chinese medicinal composition is low in side effects and the adverse reaction is avoided after patients orally take the medicines.

Description

A kind of Chinese medicine composition for the treatment of cerebral arteriosclerosis neurasthenia syndrome
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition for the treatment of cerebral arteriosclerosis neurasthenia syndrome.
Background technology
Cerebral arteriosclerosis, can cause cerebral ischemia, brain atrophy, or causes rupture of blood vessel in brain hemorrhage.The commitment of cerebral arteriosclerosis can cause neurasthenia, and emotion is abnormal, and judgement is low.Cerebral arteriosclerosis can occur when reaching middle and late stage that gait is stiff or walking is unstable, dull-witted, epileptic convulsion, apoplexy.Cerebral arteriosclerosis neurasthenia syndrome is because cerebral arteriosclerosis causes neuron degeneration, necrosis, glial cells hyperplasia, finally produces disordered brain function syndrome, clinical manifestation mainly contains giddy, headache, insomnia, forgetful, difficult concentrating, anxiety, anxiety, agitation, tired, work efficiency reduces, fearness sound, tinnitus, general malaise and lethargy etc.Can with vegetative nerve and sexual disorder.At present, treat this sick doctor trained in Western medicine and also lack more satisfactory method, applicant, through clinical trial for many years, utilizes this disease for the treatment of by Chinese herbs to achieve good effect.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of cerebral arteriosclerosis neurasthenia syndrome.Primary disease belongs to Chinese medicine " dizzy ", " headache " category, and the traditional Chinese medical science thinks that unit of the primary disease system deficiency of vital energy declines, and cloudy anemia is damaged, and muscle arteries and veins loses it and moistens foster, or heart deficiency of the kidney is damaged, and brain is hollow, caused by the reasons such as dysfunction of the spleen in transportation.Primary disease is the card of vital QI being weakened and pathogen being violent, controls suitable giving consideration to both the incidental and fundamental, with replenishing QI to invigorate the spleen, liver and kidney tonifying, the tired dredging collateral of invigorating blood circulation for the rule for the treatment of.
The object of the invention is to be achieved through the following technical solutions, the Chinese medicine composition of this treatment cerebral arteriosclerosis neurasthenia syndrome is made up of the Chinese medicine of following weight portion: Rhizoma Gymnadeniae 9-15 part, Radix Tylophorae arenicolae 15-25 part, leaf Miscanthus sacchariflorus (Maxim) Benth et Hook f 20-25 part, Radix Morindae Officinalis 5-15 part, Herba Habenariae rhodochellae 10-20 part, Fructus Kadsurae heteroclitae 10-15 part, Rhizoma Tupistrae Chinensis 8-16 part, Herba Crotalariae Ferrugineae 35-45 part, Folium Cycadis Revolute 15-25 part, Flos Tagetis Erectae 5-15 part, Herba Scutellariae indicae 12-20 part, Rhodobryum giganteum(Hook.) Par. 10-20 part.
Preferred: Rhizoma Gymnadeniae 12 parts, Radix Tylophorae arenicolae 20 parts, a leaf obtain 23 parts, Radix Morindae Officinalis 10 parts, Herba Habenariae rhodochellae 15 parts, Fructus Kadsurae heteroclitae 12 parts, Rhizoma Tupistrae Chinensis 13 parts, Herba Crotalariae Ferrugineae 40 parts, Folium Cycadis Revolute 20 parts, Flos Tagetis Erectae 10 parts, Herba Scutellariae indicae 15 parts, Rhodobryum giganteum(Hook.) Par. 16 parts.
Above-mentioned Chinese medicine decocting is made decoction by preparation method.
Fang Zhong: Rhizoma Gymnadeniae strengthening by means of tonics, spleen reinforcing lung moistening, calms the nerves relieving convulsion, QI invigorating pain relieving; Radix Tylophorae arenicolae kidney and spleen invigorating, removing toxic substances; One leaf obtains relaxing muscles and tendons to promote blood circulation, tonifying speen and tonifying kidney; Radix Morindae Officinalis, Herba Habenariae rhodochellae kidney-replenishing, wind-damp dispelling; The kidney invigorating of Fructus Kadsurae heteroclitae heart tonifying, eliminating phlegm and stopping cough; Rhizoma Tupistrae Chinensis nourishing yin and promoting blood circulation; Herba Crotalariae Ferrugineae invigorating the spleen and replenishing QI, diuretic antiinflammatory; Folium Cycadis Revolute vital energy regualting and blood circulation-promoting suppressing the hyperactive liver; Flos Tagetis Erectae is enriched blood and is stimulated the menstrual flow, promoting tissue regeneration by removing blood stasis; Herba Scutellariae indicae dispels the wind, and invigorates blood circulation, removing toxic substances, pain relieving; Rhodobryum giganteum(Hook.) Par. tranquillizing and allaying excitement, clear away heart-fire improving eyesight.
Clinical data
1. physical data is originally organized 120 examples and is out-patient, by table of random number, case stochastic averagina is divided into treatment group and matched group.Treatment group 60 example, man 35 example, female 25 example, 43 ~ 70 years old age, average 55.1 years old, the course of disease 2 months ~ 9 years.Matched group 60 example, man 37 example, female 23 example, 45 ~ 73 years old age, average 56.3 years old, the course of disease 2 months ~ 10 years.Two groups of patients compare in sex, age, the course of disease, and no significant difference (P>0.05), has comparability.
2. diagnostic criteria is with reference to " the cerebral arteriosclerosis diagnostic criteria " of the 3rd the psychoneural section academic conference revision in the whole nation in 1981, in conjunction with the armarium situation of my institute, formulate following diagnostic criteria: (1) has the clinical manifestation of neurasthenia's disease group, as dizzy, headache, one's ears rang and spots danced before one's eyes, fatigue and weakness, forgetful agitation, bradyphrenia, sleep disorder; (2) more than ocular fundus arteriosclerosis II level; (3) serum cholesterol and triglyceride increase; (4) transcranial doppler (TCD) shows cerebral arteriosclerosis; (5) in conjunction with CT scan, except can cause other disease of brain of similar clinical manifestation.
3. Therapeutic Method treatment group patient takes Chinese medicine composition of the present invention, take Rhizoma Gymnadeniae 12g, Radix Tylophorae arenicolae 20g, a leaf obtain 23g, Radix Morindae Officinalis 10g, Herba Habenariae rhodochellae 15g, Fructus Kadsurae heteroclitae 12g, Rhizoma Tupistrae Chinensis 13g, Herba Crotalariae Ferrugineae 40g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba Scutellariae indicae 15g, Rhodobryum giganteum(Hook.) Par. 16g, decocting becomes decoction, every day potion, dividing and sooner or later take for 2 times, 14th is 1 course for the treatment of; Matched group oral vitamin E0.1g, every day 3 times, nimodipine 20mg, every day 3 times, piracetam 0.8g, every day 3 times; Two groups all serve on 4 courses for the treatment of.
4. criterion of therapeutical effect is by the standard rating curative effect in " guideline of clinical investigations of new Chinese medicine treatment cerebral arteriosclerosis ".Cure: primary symptom disappears, the main Index for examination result such as TCD, blood fat, optical fundus is normal; Effective: primary symptom integration reduces by more than 70%, TCD and obviously improves, and blood fat obviously declines; Effective: primary symptom integration reduces 36%-69%, TCD and has some improvement, rate and blood-lipid decreased; Invalid: not reach above-mentioned effective standard.
5. therapeutic effect two groups treats comparitive study after 4 courses for the treatment of, and treatment group 60 example, wherein cures 35 examples (58.3%); Effective 15 examples (25.5%), effective 7 examples (11.7%), invalid 3 examples (5.0%), total effective rate 95.0%; Matched group 60 example, wherein cures 18 examples (30.0%); Effective 20 examples (33.3%), effective 11 examples (18.3%), invalid 11 examples (18.3%), total effective rate 81.7%.Two groups are compared, and treatment group cure rate, total effective rate are obviously better than matched group, have comparability.P<0.05。
Detailed description of the invention
Embodiment one: take Rhizoma Gymnadeniae 12g, Radix Tylophorae arenicolae 20g, a leaf obtains 23g, Radix Morindae Officinalis 10g, Herba Habenariae rhodochellae 15g, Fructus Kadsurae heteroclitae 12g, Rhizoma Tupistrae Chinensis 13g, Herba Crotalariae Ferrugineae 40g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba Scutellariae indicae 15g, Rhodobryum giganteum(Hook.) Par. 16g, becomes decoction by above-mentioned Chinese medicine decocting.
Embodiment two: take Rhizoma Gymnadeniae 15g, Radix Tylophorae arenicolae 25g, a leaf obtains 20g, Radix Morindae Officinalis 15g, Herba Habenariae rhodochellae 10g, Fructus Kadsurae heteroclitae 15g, Rhizoma Tupistrae Chinensis 8g, Herba Crotalariae Ferrugineae 45g, Folium Cycadis Revolute 25g, Flos Tagetis Erectae 5g, Herba Scutellariae indicae 20g, Rhodobryum giganteum(Hook.) Par. 10g, becomes decoction by above-mentioned Chinese medicine decocting.
Embodiment three: take Rhizoma Gymnadeniae 9g, Radix Tylophorae arenicolae 15g, a leaf obtains 25g, Radix Morindae Officinalis 5g, Herba Habenariae rhodochellae 20g, Fructus Kadsurae heteroclitae 10g, Rhizoma Tupistrae Chinensis 16g, Herba Crotalariae Ferrugineae 35g, Folium Cycadis Revolute 15g, Flos Tagetis Erectae 15g, Herba Scutellariae indicae 12g, Rhodobryum giganteum(Hook.) Par. 20g, becomes decoction by above-mentioned Chinese medicine decocting.

Claims (1)

1. treat the Chinese medicine composition of cerebral arteriosclerosis neurasthenia syndrome for one kind, it is characterized in that this Chinese medicine composition is made up of the Chinese medicine of following weight: Rhizoma Gymnadeniae 12g, Radix Tylophorae arenicolae 20g, leaf Miscanthus sacchariflorus (Maxim) Benth et Hook f 23g, Radix Morindae Officinalis 10g, Herba Habenariae rhodochellae 15g, Fructus Kadsurae heteroclitae 12g, Rhizoma Tupistrae Chinensis 13g, Herba Crotalariae Ferrugineae 40g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba Scutellariae indicae 15g, Rhodobryum giganteum(Hook.) Par. 16g, become decoction by above-mentioned Chinese medicine decocting.
CN201310491607.XA 2013-10-11 2013-10-11 Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome Expired - Fee Related CN103520498B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310491607.XA CN103520498B (en) 2013-10-11 2013-10-11 Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310491607.XA CN103520498B (en) 2013-10-11 2013-10-11 Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome

Publications (2)

Publication Number Publication Date
CN103520498A CN103520498A (en) 2014-01-22
CN103520498B true CN103520498B (en) 2015-06-24

Family

ID=49923085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310491607.XA Expired - Fee Related CN103520498B (en) 2013-10-11 2013-10-11 Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome

Country Status (1)

Country Link
CN (1) CN103520498B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113117019A (en) * 2021-04-22 2021-07-16 广州白云山奇星药业有限公司 Application of Longfengbao capsule in preparing medicine for preventing and treating cerebral arteriosclerosis and related diseases
CN113117020A (en) * 2021-04-22 2021-07-16 广州白云山奇星药业有限公司 Application of Longfengbao capsule in preparing medicine for preventing and treating cardiovascular disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253917B (en) * 2008-03-16 2010-10-13 蓝子花 August Zhabao health tea
CN101332234B (en) * 2008-06-06 2012-01-04 罗连珍 Traditional Chinese medicine preparation for treating neurasthenic
CN103053750A (en) * 2012-12-25 2013-04-24 蓝秀香 Healthcare rust-colored crotalaria herb tea

Also Published As

Publication number Publication date
CN103520498A (en) 2014-01-22

Similar Documents

Publication Publication Date Title
CN102078510B (en) Chinese medicinal composition for treating coronary heart disease
CN103316141B (en) Traditional Chinese medicine composition for treating cervical spondylosis
CN103520498B (en) Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome
CN102670995A (en) Group of pure traditional Chinese medicinal formula for treating cardiovascular and cerebrovascular diseases and preparation method of same
CN104587225A (en) Traditional Chinese medicine composition for treating cervical spondylosis
CN102641471B (en) Traditional Chinese medicine for treating cholelithiasis
CN106177516A (en) A kind of Chinese powder medicine for treating cervical spondylosis
CN102430030B (en) Chinese medicinal composition for treating bone impediment
CN102579941B (en) Drug for treating lumbar intervertebral disc herniation with pain as well as preparation method of oral liquid of drug
CN105250809A (en) Traditional Chinese medicine composition for treating dermatomyositis
CN104623542A (en) Traditional Chinese medicine composition for treating cervical spondylosis
CN103893480A (en) Traditional Chinese medicine preparation for treating kidney deficiency and blood stasis type oviduct obstructive infertility
CN104189102B (en) A kind of Chinese medicine composition and preparation method thereof
CN103463340A (en) Traditional Chinese medicine preparation for treating hemicrania
CN105232744A (en) Traditional Chinese medicine composition for treating lumbago
CN105434818A (en) Traditional Chinese medicine preparation for treating cervical spondylosis
CN105287769A (en) Acupoint naturopathy for treating neck diseases
CN105687699A (en) Traditional Chinese medicine composition for treating vital myocarditis
CN102716262B (en) Traditional Chinese medicine formula for curing ankylosing spondylitis
CN104958504A (en) Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition
CN104288604A (en) Traditional Chinese medicine composition for treating cerebral infarction
CN104666824A (en) Traditional Chinese medicinal composition for treating psoriasis
CN103463482B (en) Traditional Chinese medicinal preparation for treating intractable angina
CN104758504A (en) Traditional Chinese medicine composition for treating cervical spondylosis
CN104225435A (en) Traditional Chinese medicine preparation for treating turbid phlegm obstructing type coronary heart disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150624

Termination date: 20151011

EXPY Termination of patent right or utility model